Regulations, Legislation & Enforcement

State of the US Dietary Supplements sector in 2023

STATE OF THE INDUSTRY SURVEY

State of the US Dietary Supplements sector in 2023

By Stephen Daniells

Are supply chains still causing problems for businesses? What are the hottest ingredients and most sought-after product claims? And do people really think about FDA’s recent actions against ingredients like NAC and NMN?

Lawsuit against FDA on NMN ‘certainly being considered’, says NPA CEO

Lawsuit against FDA on NMN ‘certainly being considered’, says NPA CEO

By Stephen Daniells

The Natural Products Association is hoping the US Food & Drug Administration is responsive to its recent Citizen’s Petition on the status of NMN, but if it’s not then other options are being considered, Dr Daniel Fabricant, NPA’s CEO tells NutraIngredients-USA.

What to expect from the International Conference on the Science of Botanicals

Oxford ICSB: ‘You always learn something from this meeting’

By Stephen Daniells

From authentication and identification of botanicals to approached to establishing safety and efficacy, the 21st International Conference on the Science of Botanicals (ICSB) provides stakeholders in the botanicals space a unique opportunity to learn and...

Steve Mister on FDA, MPL, CBD, and CRN at 50

Steve Mister on proposed FDA reorg, MPL, CBD, and CRN at 50

By Stephen Daniells

The first month of 2023 is over, and already there’s some big developments (or non-developments in the case of CBD) for the US dietary supplements industry. We caught up with Steve Mister, president and CEO of the Council for Responsible Nutrition, to...

5 take-aways we learned during our Business Leaders Forum

5 take-aways we learned during our Business Leaders Forum

By Stephen Daniells

From 2022 sales numbers to consumer enthusiasm remaining high, and from progress with equality and diversity in the industry to the growth in awareness around the importance of the microbiome for health, there were lots of talking points from our 3rd...

Getty Images / skynesher

Drumroll, please… waiting game continues to plague CBD industry

By Danielle Masterson

Rumors about a big FDA announcement began swirling earlier this week, with the industry bracing for a potential end to a five-year wait on the regulatory future of CBD. But, much like the last few years, CBD professionals were left waiting without answers,...

©Getty Images - JStudios

MusclePharm assets to be sold at auction

By Hank Schultz

The intellectual property of MusclePharm, a sports nutrition brand that had a meteoric rise and an equally spectacular fall, will be sold at an auction on Thursday, Dec. 15.

Getty images / skynesher

CBD in 2022: A year in review

By Danielle Masterson

We’re five years in, so what does the CBD industry look like now and what can we expect in 2023? We spoke with several CBD experts who walked us through the highs and lows of 2022.

Getty | handmade pictures

Collaborate to reduce energy drink health risks, scientists warn

By Nicola Gordon-Seymour

Scientists are calling for a European legal framework for energy drinks (EDs) to regulate maximum levels of active components, volume size, and initiate labelling improvements to mitigate health risks from excessive exposure.

AHPA’s McGuffin on supply chain, MPL, climate change, and more

AHPA’s McGuffin on supply chain, MPL, climate change, and more

By Stephen Daniells

Supply chain issues appear to be easing for the herbal supplements sector, says Michael McGuffin, president of the American Herbal Products Association, but the key lesson from the past couple of years is that supply chain management is not simple.

‘Warning letter geek’ decodes marketing compliance

‘Warning letter geek’ decodes marketing compliance

By Danielle Masterson

Asa Waldstein is principal of the Supplement Advisory Group and the man behind 'Warning Letter Wednesdays.' His bread and butter is educating companies about the dos and don'ts of marketing.

©Getty Images - Ildo Frazao

FDA’s takedown of NMN raises fairness, transparency concerns

By Hank Schultz

NMN, an anti-aging ingredient, has been disallowed by FDA because of its prior investigation as a drug. The determination, which came as something of a surprise given the ingredient’s market history, has raised questions of fairness and transparency.

Follow us

Products

View more

Webinars